Development and implementation of a 384-well homogeneous fluorescence intensity high-throughput screening assay to identify mitogen-activated protein kinase phosphatase-1 dual-specificity protein phosphatase inhibitors.
about
Automated high-content live animal drug screening using C. elegans expressing the aggregation prone serpin α1-antitrypsin ZPharmacological targeting of the mitochondrial phosphatase PTPMT1.HCS campaign to identify selective inhibitors of IL-6-induced STAT3 pathway activation in head and neck cancer cell linesEpigenetic assays for chemical biology and drug discovery.Development and validation of a high-content screening assay to identify inhibitors of cytoplasmic dynein-mediated transport of glucocorticoid receptor to the nucleus.In vivo structure-activity relationship studies support allosteric targeting of a dual specificity phosphatase.Implementation of a 220,000-compound HCS campaign to identify disruptors of the interaction between p53 and hDM2 and characterization of the confirmed hits.Reducing agents affect inhibitory activities of compounds: results from multiple drug targets.Cdc25B dual-specificity phosphatase inhibitors identified in a high-throughput screen of the NIH compound library.Profiling the NIH Small Molecule Repository for compounds that generate H2O2 by redox cycling in reducing environments.Characterization and optimization of a novel protein-protein interaction biosensor high-content screening assay to identify disruptors of the interactions between p53 and hDM2.Identifying actives from HTS data sets: practical approaches for the selection of an appropriate HTS data-processing method and quality control review.High-content positional biosensor screening assay for compounds to prevent or disrupt androgen receptor and transcriptional intermediary factor 2 protein-protein interactions.Development and validation of a robust and sensitive assay for the discovery of selective inhibitors for serine/threonine protein phosphatases PP1α (PPP1C) and PP5 (PPP5C).Development of a 384-well colorimetric assay to quantify hydrogen peroxide generated by the redox cycling of compounds in the presence of reducing agents.Redox cycling compounds generate H2O2 in HTS buffers containing strong reducing reagents--real hits or promiscuous artifacts?Reconfiguring the AR-TIF2 Protein-Protein Interaction HCS Assay in Prostate Cancer Cells and Characterizing the Hits from a LOPAC Screen.Characterisation of the PTEN inhibitor VO-OHpicHAMS: High-Affinity Mass Spectrometry Screening. A High-Throughput Screening Method for Identifying the Tightest-Binding Lead Compounds for Target Proteins with No False Positive IdentificationsA Tumor Cell-Selective Inhibitor of Mitogen-Activated Protein Kinase Phosphatases Sensitizes Breast Cancer Cells to Lymphokine-Activated Killer Cell Activity.New Approaches to Difficult Drug Targets: The Phosphatase Story
P2860
Q21562132-02E58499-1F0E-4DB7-B9C1-B09BCDC38EF7Q30273891-C9B8AAF3-CEDE-4694-BE62-3698364F7B2DQ30278790-00B31A5B-585C-4D64-9DC8-3CE1FD1B086CQ30358152-2FF035A5-01DB-48B1-9529-27A09D8A252EQ30416877-960E1B3B-E29C-4EAA-8DC5-F77300556599Q30585632-7C5E5BDC-0F14-4CB4-8C7E-77C32B8E85CDQ30985752-55BE42AC-545C-414F-8A49-2721C7E86DB1Q31048549-428CE073-C7E2-46E7-816D-9ADE9C6C7DA4Q33468576-CE1F2761-1F09-46A6-B14C-E8BB49161860Q33523595-F3AA3BEB-DDF4-405E-813D-05509F1385F5Q33642043-F7C6A73A-40FC-44EE-8287-08E1F62A44C1Q33772474-BD570893-CB4F-45DB-8C08-ABA6BFAE0B4CQ34097208-40A92213-D2B7-4391-93FC-82AF4B65D20BQ35406908-204AFC61-99AF-4E9F-99DD-D07AA6B651FBQ37364643-643100EF-2BDD-445F-A6E7-8B64AAF379DAQ37809299-CD88FFEA-3E82-439A-B7F9-1546BF8B8444Q38747617-70922990-FCA4-495A-B12F-81ABFE60949BQ39742541-7A22AC9B-57CD-4C9D-BE98-7CFCB114C19CQ42677543-931ED519-E5EE-44A3-9904-91F7222CB6F3Q46423964-FFDFAABD-DD45-44E1-B6F0-CCA4D5C01CE7Q56513340-A3F48AB4-97F7-4F8D-B6AE-080660D098CE
P2860
Development and implementation of a 384-well homogeneous fluorescence intensity high-throughput screening assay to identify mitogen-activated protein kinase phosphatase-1 dual-specificity protein phosphatase inhibitors.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Development and implementation ...... rotein phosphatase inhibitors.
@ast
Development and implementation ...... rotein phosphatase inhibitors.
@en
Development and implementation ...... rotein phosphatase inhibitors.
@nl
type
label
Development and implementation ...... rotein phosphatase inhibitors.
@ast
Development and implementation ...... rotein phosphatase inhibitors.
@en
Development and implementation ...... rotein phosphatase inhibitors.
@nl
prefLabel
Development and implementation ...... rotein phosphatase inhibitors.
@ast
Development and implementation ...... rotein phosphatase inhibitors.
@en
Development and implementation ...... rotein phosphatase inhibitors.
@nl
P50
P356
P1476
Development and implementation ...... rotein phosphatase inhibitors.
@en
P2093
Caleb A Foster
Sunita Shinde
P304
P356
10.1089/ADT.2007.066
P577
2007-06-01T00:00:00Z